Evaluation of Methenolone Enanthate Efficacy in Preventing MRONJ : A Randomized Trial on Rats
Journal of Oral Pathology & Medicine · 2024
DOI: 10.1111/jop.13574 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Oral Pathology & Medicine, 2024. Verfasst von Gökhan Gürses und 3 weiteren Autor:innen. Beteiligte Einrichtung: Dentistry Faculty, Department of Oral and Maxillofacial Surgery, Selcuk University, Konya, Turkey. Hauptthemen laut MEDLINE: Rats, Wistar, Bisphosphonate-Associated Osteonecrosis of the Jaw. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Selçuk University Research Foundation.
Abstract (Originalsprache)
Background
It is well‐known that oral surgical procedures pose a high risk for medication‐related osteonecrosis of the jaw in patients taking bisphosphonates. Although some position papers and guidelines have been published with regard to its treatment, few studies have investigated prevention methods. This study investigates the effectiveness of methenolone enanthate, an anabolic steroid, for the prevention of medication‐related osteonecrosis of the jaw.
Methods
Thirty‐six Wistar rats were divided into three groups. Two experimental groups, Z and ZM, took zoledronic acid for 6 weeks prior to extraction of the left maxillary first molar. The Group ZM also was given methenolone enanthate continuously for 1 week before and 4 weeks after the extraction. The control group was not given any medication. The rats were euthanized 5 weeks after extraction. The extraction socket was evaluated clinically for bone exposure and histologically for inflammation, hyperemia, collagen fibers, epithelialization, number of osteoclasts, and empty lacunae.
Results
Six rats died during the experimental research. The bone exposure rate, mean numbers of attached osteoclasts (in 40× magnification), and empty lacunae (in 100× magnification) were 0%, 4%, and 0.8% in Group C; 75%, 1%, and 8% in Group Z; and 10%, 2.1%, and 3% in Group ZM, respectively. Significant differences exist between all groups regarding the number of empty lacunae. There were significant differences between Group C/ZM and Group Z in terms of bone exposure rate, inflammation, hyperemia, collagen fiber organization, and epithelialization.
Conclusion
In our tested preclinical model, methenolone enanthate has shown potential for preventing medication‐related osteonecrosis of the jaw.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dentistry Faculty, Department of Oral and Maxillofacial Surgery, Selcuk University, Konya, Turkey.
- Veterinary Faculty, Department of Histology, Selcuk University, Konya, Turkey.
- Private Practitioner.
- Medicine Faculty, Department of Biostatistics, Selcuk University, Konya, Turkey.
ORCID-Profile: Gökhan Gürses
Förderung
- Selçuk University Research Foundation
Zitieren
APA
Gürses, G., Sur, E., Cengiz, Z. O., & Körez, M. K. (2024). Evaluation of Methenolone Enanthate Efficacy in Preventing MRONJ : A Randomized Trial on Rats. Journal of Oral Pathology & Medicine. https://doi.org/10.1111/jop.13574
Vancouver
Gürses G, Sur E, Cengiz ZO, Körez MK. Evaluation of Methenolone Enanthate Efficacy in Preventing MRONJ : A Randomized Trial on Rats. Journal of Oral Pathology & Medicine. 2024. doi:10.1111/jop.13574
BibTeX
@article{Grses2024,
author = {Gürses, Gökhan and Sur, Emrah and Cengiz, Ziya Ozan and Körez, Muslu Kazım},
title = {Evaluation of Methenolone Enanthate Efficacy in Preventing MRONJ : A Randomized Trial on Rats},
journal = {Journal of Oral Pathology & Medicine},
year = {2024},
doi = {10.1111/jop.13574}
}
EUVIMED